0001104659-23-010490.txt : 20230203 0001104659-23-010490.hdr.sgml : 20230203 20230203160831 ACCESSION NUMBER: 0001104659-23-010490 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230201 FILED AS OF DATE: 20230203 DATE AS OF CHANGE: 20230203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Meeker David P CENTRAL INDEX KEY: 0001385155 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38223 FILM NUMBER: 23585844 MAIL ADDRESS: STREET 1: C/O PENWEST PHARMACEUTICALS CO STREET 2: 39 OLD RIDGEBURY ROAD SUITE 11 CITY: DANBURY STATE: CT ZIP: 06810 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001649904 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462159271 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 857-264-4280 MAIL ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: RHYTHM METABOLIC, INC. DATE OF NAME CHANGE: 20150803 4 1 tm235340-4_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2023-02-01 0 0001649904 RHYTHM PHARMACEUTICALS, INC. RYTM 0001385155 Meeker David P C/O RHYTHM PHARMACEUTICALS, INC. 222 BERKELEY STREET, 12TH FLOOR BOSTON MA 02116 1 1 0 0 President and CEO Restricted Stock Units 2023-02-01 4 A 0 56500 0 A Common Stock 56500 56500 D Stock Option (Right to Buy) 27.35 2023-02-01 4 A 0 229600 0 A 2033-01-31 Common Stock 229600 229600 D Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. /s/ Hunter C. Smith, Attorney-in-Fact for David P. Meeker 2023-02-03